Asciminib

The FDA granted accelerated approval to asciminib for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

In this video, Eric Winer, MD, discusses the results of research into chronic myeloid leukemia presented at ASCO Annual Meeting.

In this episode of Meeting Mic, we continue to bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia.

In this video, Christine McMahon, MD, discusses the results of the phase 3 ASC4FIRST study, pertaining to chronic myelogenous leukemia, presented at ASCO Annual Meeting.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio’s top headlines from the meeting.

CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO Annual Meeting.

CHICAGO — Asciminib continued to confer superior efficacy and better safety and tolerability than bosutinib among patients with chronic-phase chronic myeloid leukemia, according to study results presented during ASCO Annual Meeting.

The FDA granted breakthrough therapy designation to asciminib for treatment of certain patients with chronic myeloid leukemia.

Asciminib appeared to be more effective than bosutinib for certain patients with chronic-phase chronic myeloid leukemia who had been treated with at least two tyrosine kinase inhibitors, according to results of the phase 3 ASCEMBL study.